{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166104997",
    "name" : "Annotation of CPIC Guideline for abacavir and HLA-B",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [
      {
        "id" : 1447983436,
        "name" : "CPIC® Guideline for Abacavir and HLA-B – CPIC",
        "resource" : "URL",
        "resourceId" : "https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/",
        "_url" : "https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/",
        "version" : 1
      }
    ],
    "descriptiveVideoId" : "-ho-Se249_8",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1183699748,
        "date" : "2012-02-29T00:00:00-08:00",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1183847536,
        "date" : "2014-02-28T00:00:00-08:00",
        "description" : "CPIC update to guidelines published",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1184512476,
        "date" : "2014-08-05T00:00:00-07:00",
        "description" : "updated pubication date for update to May 2014",
        "type" : "Update",
        "version" : 1
      },
      {
        "id" : 1184782525,
        "date" : "2014-09-30T00:00:00-07:00",
        "description" : "Supplement was missing figures; complete supplement with figures added",
        "type" : "Correction",
        "version" : 1
      },
      {
        "id" : 1451461940,
        "date" : "2021-06-16T18:33:15.314-07:00",
        "description" : "Added text from guideline regarding pediatrics",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452134900,
        "date" : "2023-06-20T22:38:45.080-07:00",
        "description" : "Added supplemental file links",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15070904,"title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994233","crossReferences":[{"id":1449279728,"resource":"PubMed Central","resourceId":"PMC3994233","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994233"},{"id":1449279727,"resource":"PubMed","resourceId":"24561393","_url":"https://www.ncbi.nlm.nih.gov/pubmed/24561393"},{"id":1449279729,"resource":"DOI","resourceId":"10.1038/clpt.2014.38","_url":"http://dx.doi.org/10.1038%2Fclpt.2014.38"}],"objCls":"Literature","pubDate":"2014-05-01T00:00:00-07:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"},
      {"id":14962778,"title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374459","crossReferences":[{"id":1449267214,"resource":"PubMed Central","resourceId":"PMC3374459","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374459"},{"id":827848488,"resource":"PubMed","resourceId":"22378157","_url":"https://www.ncbi.nlm.nih.gov/pubmed/22378157"},{"id":1449267215,"resource":"DOI","resourceId":"10.1038/clpt.2011.355","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.355"}],"objCls":"Literature","pubDate":"2012-04-01T00:00:00-07:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : true,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Haplotype",
        "id" : "PA165987830",
        "symbol" : "HLA-B*57:01",
        "name" : "*57:01",
        "version" : 6
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA448004",
        "name" : "abacavir",
        "version" : 11
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA35056",
        "symbol" : "HLA-B",
        "name" : "major histocompatibility complex, class I, B",
        "version" : 40
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447982036,
      "html" : "<p>In individuals with the HLA-B*57:01 variant allele (&quot;HLA-B*57:01-positive&quot;), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451433650,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/\" target=\"_blank\">CPIC&reg; guideline for abacavir and HLA-B</a>.</p>\n<h3 id=\"may-2014-update\">May 2014 Update</h3>\n<p><em>Accepted article preview online 21 February 2014; Advance online publication 12 March 2014</em></p>\n<p>The <a rel=\"noopener noreferrer\" href=\"http://www.nature.com/clpt/journal/v95/n5/full/clpt201438a.html\" target=\"_blank\">2014 update of CPIC guidelines</a> regarding abacavir has been published in <em>Clinical Pharmacology and Therapeutics</em>. Literature published between April 2011-November 2013 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>\n<ul>\n<li>These guidelines are applicable to:\n<ul>\n<li>HIV Patients</li>\n<li>&quot;Although much of the evidence linking HLA- B*57:01 to abacavir hypersensitivity was conducted in adults, there is no reason to suspect that children positive for HLA- B*57:01 would be at less risk for abacavir hypersensitivity reactions than adults positive for HLA-B*57:01. Furthermore, the Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection; http://aidsinfo.nih.gov/con- tentfiles/lvguidelines/pediatricguidelines.pdf ) recommends against the use of abacavir in children who test positive for HLA-B*57:01.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/abacavir/2014/24561393.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing: 2014 Update </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/abacavir/2014/24561393-supplement.pdf\" target=\"_blank\">2014 supplement</a></li>\n<li><a href=\"https://www.pharmgkb.org/page/hlabRefMaterials\">HLA Gene-Specific Information Tables</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/drug_resource/abacavir-Drug_Resource_Mappings.xlsx\" target=\"_blank\">Abacavir Drug Resource Mappings</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/test_alert/abacavir_Pre_and_Post_Test_Alerts.xlsx\" target=\"_blank\">Abacavir Pre and Post Tests Alerts</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/images/flow_chart/Abacavir_CDS_Flow_Chart.jpg\" target=\"_blank\">Abacavir Clinical Decision Support Flow Chart</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"april-2012\">April 2012</h3>\n<p><em>Advance online publication February 2012</em></p>\n<ul>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/abacavir/2012/22378157.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/abacavir/2012/22378157-supplement.pdf\" target=\"_blank\">2012 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<p>Excerpt from the abacavir dosing guidelines:</p>\n<blockquote class=\"blockquote\">\n<p>We agree with others* that <em>HLA-B*57:01</em> screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are <em>HLA-B*57:01</em>-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk.</p>\n</blockquote>\n<p>*[Articles:<a href=\"/pmid/18826546\">18826546</a>, <a href=\"/pmid/19640227\">19640227</a>, <a href=\"/pmid/21174626\">21174626</a>, <a href=\"/pmid/21412232\">21412232</a>] <a rel=\"noopener noreferrer\" href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) </a></p>\n<h3 id=\"table-1-recommended-therapeutic-use-of-abacavir-based-on-hla-b-genotype\">Table 1: Recommended therapeutic use of abacavir based on <em>HLA-B</em> genotype</h3>\n<p><em>Adapted from Tables 1 and 2 of the 2012 guideline manuscript.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Likely phenotype</th>\n<th>Genotypes</th>\n<th>Examples of diplotypes</th>\n<th>Implications for phenotypic measures</th>\n<th>Recommendations for abacavir therapy</th>\n<th>Classification of recommendation for abacavir therapy <sup>a</sup></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Very low risk of hypersensitivity (constitutes ~94% <sup>b</sup> of patients)</td>\n<td>Absence of <em>*57:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td>\n<td>*X/*X <sup>c</sup></td>\n<td>Low or reduced risk of abacavir hypersensitivity</td>\n<td>Use abacavir per standard dosing guidelines</td>\n<td>Strong</td>\n</tr>\n<tr>\n<td>High risk of hypersensitivity (~6% of patients)</td>\n<td>Presence of at least one <em>*57:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td>\n<td><em>*57:01</em>/*X <sup>c</sup> <em>*57:01/*57:01</em></td>\n<td>Significantly increased risk of abacavir hypersensitivity</td>\n<td>Abacavir is not recommended</td>\n<td>Strong</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> Rating scheme described in the <a download=\"CPIC_HLAB-Abacavir_Supplemental_Material.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a></p>\n<p><sup>b</sup> See the <a download=\"CPIC_HLAB-Abacavir_Supplemental_Material.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a> for estimates of genotype frequencies among different ethnic/geographic groups</p>\n<p><sup>c</sup> *X = any <em>HLA-B</em> genotype other than <em>*57:01</em>.</p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n<p><strong>Listen to an interview with the lead author:</strong> <a rel=\"noopener noreferrer\" href=\"http://www.theaidsreader.com/display/article/1145619/2064707\" target=\"_blank\">podcast</a></p>\n",
      "version" : 2
    },
    "version" : 49
  }
}